+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sangamo Therapeutics Inc (SGMO) - Financial and Strategic SWOT Analysis Review

Sangamo Therapeutics Inc (SGMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of hemophilia A and B, Huntington's disease, Fabry disease, Alzheimer's disease, and others. Its ZFPs-based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and the production of transgenic animals. Sangamo is headquartered in Richmond, California, the US.

Sangamo Therapeutics Inc Key Recent Developments

  • May 09, 2024: Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
  • May 09, 2024: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
  • May 02, 2024: Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
  • Apr 22, 2024: Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Sangamo Therapeutics Inc - Key Facts
  • Sangamo Therapeutics Inc - Key Employees
  • Sangamo Therapeutics Inc - Key Employee Biographies
  • Sangamo Therapeutics Inc - Major Products and Services
  • Sangamo Therapeutics Inc - History
  • Sangamo Therapeutics Inc - Company Statement
  • Sangamo Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Sangamo Therapeutics Inc - Business Description
  • R&D Overview
  • Sangamo Therapeutics Inc - Corporate Strategy
  • Sangamo Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Sangamo Therapeutics Inc - Strengths
  • Sangamo Therapeutics Inc - Weaknesses
  • Sangamo Therapeutics Inc - Opportunities
  • Sangamo Therapeutics Inc - Threats
  • Sangamo Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Sangamo Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 09, 2024: Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
  • May 09, 2024: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
  • May 02, 2024: Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
  • Apr 22, 2024: Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  • Mar 22, 2024: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
  • Mar 13, 2024: Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
  • Mar 12, 2024: Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
  • Oct 25, 2023: Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
  • Apr 27, 2023: Sangamo Therapeutics announces strategic update and reports preliminary First Quarter 2023 financial results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Sangamo Therapeutics Inc, Key Facts
  • Sangamo Therapeutics Inc, Key Employees
  • Sangamo Therapeutics Inc, Key Employee Biographies
  • Sangamo Therapeutics Inc, Major Products and Services
  • Sangamo Therapeutics Inc, History
  • Sangamo Therapeutics Inc, Subsidiaries
  • Sangamo Therapeutics Inc, Key Competitors
  • Sangamo Therapeutics Inc, Ratios based on current share price
  • Sangamo Therapeutics Inc, Annual Ratios
  • Sangamo Therapeutics Inc, Interim Ratios
  • Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Sangamo Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Sangamo Therapeutics Inc, Performance Chart (2019 - 2023)
  • Sangamo Therapeutics Inc, Ratio Charts
  • Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Spark Therapeutics Inc
  • Acceleron Pharma Inc
  • Abata Therapeutics
  • Lyell Immunopharma Inc
  • Genzyme Corp
  • AZTherapies Inc
  • bluebird bio Inc
  • TeraImmune Inc
  • Sigilon Therapeutics Inc
  • Precision Biosciences Inc
  • Novo Nordisk Inc
  • Cellectis SA
  • Taysha Gene Therapies Inc
  • Pfizer Inc
  • Merck & Co Inc
  • GSK plc
  • 4D Molecular Therapeutics Inc
  • Protalix BioTherapeutics Inc
  • Editas Medicine Inc
  • Amgen Inc
  • Cellenkos Inc
  • BioMarin Pharmaceutical Inc
  • Vertex Pharmaceuticals Inc
  • Sonoma Biotherapeutics Inc
  • Quell Therapeutics Ltd
  • Novartis Corp
  • GentiBio Inc
  • Genentech USA Inc
  • CRISPR Therapeutics AG
  • Beam Therapeutics Inc
  • Allogene Therapeutics Inc